Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord blood

Patrick J. Hanley; Catherine M. Bollard; Claudio G. Brunstein

doi:10.1016/j.jcyt.2014.12.007

Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord blood

Patrick J. Hanley, Catherine M. Bollard, Claudio G. Brunstein

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Review article › peer-review

16 Scopus citations

Abstract

Cord blood transplantation, an alternative to traditional stem cell transplants (bone marrow or peripheral blood stem cell transplantation), is an attractive option for patients lacking suitable stem cell transplant donors. Cord blood units have also proven to be a valuable donor source for the development of cellular therapeutics. Virus-specific T cells and regulatory T cells are two cord blood-derived products that have shown promise in early-phase clinical trials to prevent and/or treat viral infections and graft-versus-host disease, respectively. We describe how current strategies that use cord blood-derived regulatory T cells and virus-specific T cells have been developed to improve outcomes for cord blood transplant recipients.

Original language	English (US)
Pages (from-to)	749-755
Number of pages	7
Journal	Cytotherapy
Volume	17
Issue number	6
DOIs	https://doi.org/10.1016/j.jcyt.2014.12.007
State	Published - Jun 1 2015

Bibliographical note

Publisher Copyright:
© 2015 International Society for Cellular Therapy.

Keywords

Antiviral
Cell therapy
Cord blood
Graft-versus-host disease
Immunotherapy
Regulatory t cells (Treg)
Transplant

Access

10.1016/j.jcyt.2014.12.007

OpenUrl availability

Full text

Cite this

@article{73d09b1e39bb42d394ea2cf8faae9731,

title = "Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord blood",

abstract = "Cord blood transplantation, an alternative to traditional stem cell transplants (bone marrow or peripheral blood stem cell transplantation), is an attractive option for patients lacking suitable stem cell transplant donors. Cord blood units have also proven to be a valuable donor source for the development of cellular therapeutics. Virus-specific T cells and regulatory T cells are two cord blood-derived products that have shown promise in early-phase clinical trials to prevent and/or treat viral infections and graft-versus-host disease, respectively. We describe how current strategies that use cord blood-derived regulatory T cells and virus-specific T cells have been developed to improve outcomes for cord blood transplant recipients.",

keywords = "Antiviral, Cell therapy, Cord blood, Graft-versus-host disease, Immunotherapy, Regulatory t cells (Treg), Transplant",

author = "Hanley, {Patrick J.} and Bollard, {Catherine M.} and Brunstein, {Claudio G.}",

note = "Publisher Copyright: {\textcopyright} 2015 International Society for Cellular Therapy.",

year = "2015",

month = jun,

day = "1",

doi = "10.1016/j.jcyt.2014.12.007",

language = "English (US)",

volume = "17",

pages = "749--755",

journal = "Cytotherapy",

issn = "1465-3249",

publisher = "Informa Healthcare",

number = "6",

}

TY - JOUR

T1 - Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord blood

AU - Hanley, Patrick J.

AU - Bollard, Catherine M.

AU - Brunstein, Claudio G.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Cord blood transplantation, an alternative to traditional stem cell transplants (bone marrow or peripheral blood stem cell transplantation), is an attractive option for patients lacking suitable stem cell transplant donors. Cord blood units have also proven to be a valuable donor source for the development of cellular therapeutics. Virus-specific T cells and regulatory T cells are two cord blood-derived products that have shown promise in early-phase clinical trials to prevent and/or treat viral infections and graft-versus-host disease, respectively. We describe how current strategies that use cord blood-derived regulatory T cells and virus-specific T cells have been developed to improve outcomes for cord blood transplant recipients.

AB - Cord blood transplantation, an alternative to traditional stem cell transplants (bone marrow or peripheral blood stem cell transplantation), is an attractive option for patients lacking suitable stem cell transplant donors. Cord blood units have also proven to be a valuable donor source for the development of cellular therapeutics. Virus-specific T cells and regulatory T cells are two cord blood-derived products that have shown promise in early-phase clinical trials to prevent and/or treat viral infections and graft-versus-host disease, respectively. We describe how current strategies that use cord blood-derived regulatory T cells and virus-specific T cells have been developed to improve outcomes for cord blood transplant recipients.

KW - Antiviral

KW - Cell therapy

KW - Cord blood

KW - Graft-versus-host disease

KW - Immunotherapy

KW - Regulatory t cells (Treg)

KW - Transplant

UR - http://www.scopus.com/inward/record.url?scp=84928998289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928998289&partnerID=8YFLogxK

U2 - 10.1016/j.jcyt.2014.12.007

DO - 10.1016/j.jcyt.2014.12.007

M3 - Review article

C2 - 25632003

AN - SCOPUS:84928998289

SN - 1465-3249

VL - 17

SP - 749

EP - 755

JO - Cytotherapy

JF - Cytotherapy

IS - 6

ER -

Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord blood

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this